Drug research
131I-apamistamab
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AMLNCT07157514 | Actinium Pharmaceuticals | Phase 2, Phase 3 | Not yet recruiting | 2029-02Estimated |
Regulatory dates and decisions
| No regulatory events published here yet.Events appear after automated checks of their supporting sources. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |